Antihypertensive effects of double the maximum dose of valsartan in African–American patients with type 2 diabetes mellitus and albuminuria
Authors:
- Matthew R WeirMWMatthew R Weir
- Norman K HollenbergNHNorman K Hollenberg
- Dion H ZappeDZDion H Zappe
- Xiangyi MengXMXiangyi Meng
- Hans-Henrik ParvingHPHans-Henrik Parving
- Giancarlo VibertiGVGiancarlo Viberti
- Giuseppe RemuzziGiuseppe Remuzzi
- 1 January 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 28 (1) , 186-193
Abstract
The blood pressure (BP)-lowering response to renin-angiotensin-aldosterone system blockade in hypertensive African-Americans is typically less than in whites. To determine whether higher than conventional doses of renin-angiotensin-aldosterone system blockade can improve BP reduction in African-American patients. Hypertensive patients with type 2 diabetes and albuminuria were enrolled: 110 African-Americans (BP = 150/87 mmHg, aged 57.5 +/- 11 years) and 281 non-African-Americans (BP = 151/89 mmHg, aged 57.7 +/- 11 years). All patients received valsartan 160 mg once daily in the morning for 4 weeks, following which patients were randomized to receive one of three valsartan doses: 160, 320 or 640 mg/day (2x, maximal recommended dose) for 26 weeks. If at week 6, target BP (<130/80 mmHg) was not achieved, then other add-on antihypertensives were allowed. The predominant BP (DeltaSBP/DeltaDBP) reduction was observed within 4 weeks and was lesser in African-Americans (7.8 +/- 15/4.5 +/- 9 mmHg) than non-African-Americans (8.9 +/- 14/6.6 +/- 1 mmHg, P < 0.05). Greater reduction in urinary albumin excretion was observed with higher doses (320 or 640 mg); however, the responses were similar between African-Americans and non-African-Americans. Use of add-on antihypertensives was higher in African-American (56%) vs. non-African-American patients (36%) with a similar rate across the three valsartan doses. From week 4-26, reduction in BP was lesser (P < 0.05) for African-American than non-African-American patients at the160-mg dose but not with 320 and 640-mg doses. In African-American patients, a lower BP reduction response was observed to conventional doses of valsartan than non-African-American patients, but at 640 mg, a higher response was observed in African-American patients than in non-African-American patients.Keywords
This publication has 15 references indexed in Scilit:
- Albuminuria response to very high-dose valsartan in type 2 diabetes mellitusJournal Of Hypertension, 2007
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Management of High Blood Pressure in African AmericansConsensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in BlacksArchives of internal medicine (1960), 2003
- Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive NephrosclerosisA Randomized Controlled TrialJAMA, 2001
- Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ DamageCurrent Medical Research and Opinion, 2000
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 1998
- Influence of Race and Dietary Salt on the Antihypertensive Efficacy of an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Antagonist in Salt-Sensitive HypertensivesHypertension, 1998
- Population characteristics and the modulation of the renin-angiotensin system in the treatment of hypertensionJournal of Human Hypertension, 1997
- Differing Mechanisms of Action of Angiotensin-Converting Enzyme Inhibition in Black and White Hypertensive PatientsHypertension, 1995
- Salt intake and hypertensive renal injury in African-Americans a therapeutic perspectiveAmerican Journal of Hypertension, 1995